Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + vincristine + prednisone + tositumomab + iodine I 131 tositumomab
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of four drugs—cyclophosphamide, vincristine, prednisone (collectively known as the CVP chemotherapy regimen)—plus the radioimmunotherapy agent Bexxar, which is composed of two components: the monoclonal antibody tositumomab and its radiolabeled form, iodine I 131 tositumomab. Cyclophosphamide is an alkylating agent that interferes with DNA replication; vincristine is a vinca alkaloid that inhibits microtubule formation; and prednisone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects. Tositumomab targets the CD20 antigen on B lymphocytes. When conjugated to radioactive iodine (I 131), it delivers targeted radiation to CD20-positive cells in addition to mediating immune cell killing via antibody-dependent mechanisms. This combination has been studied primarily for follicular non-Hodgkin lymphoma, especially in patients refractory to rituximab or relapsed after chemotherapy[1][2][3][4][8].
- Other names
- CVP + Bexxar regimen
02
Targets
CD20 (B-lymphocyte antigen CD20)DNAGR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cyclophosphamide + vincristine + prednisone + tositumomab + iodine I 131 tositumomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + vincristine + prednisone + tositumomab + iodine I 131 tositumomab.